An IgG3 switch variant of rituximab mediates enhanced complement‐dependent cytotoxicity against tumour cells with low CD20 expression levels. (7th January 2013) - Rösner, Thies; Derer, Stefanie; Kellner, Christian; Dechant, Michael; Lohse, Stefan; Vidarsson, Gestur; Peipp, Matthias; Valerius, Thomas